Added to YB: 2025-05-14
Pitch date: 2025-05-11
TEVA [neutral]
Teva Pharmaceutical Industries Limited
+69.73%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$30.7B
Pitch Price
$56.50
Price Target
27.00 (-72%)
Dividend
N/A
EV/EBITDA
9.65
P/E
43.30
EV/Sales
2.72
Sector
Pharmaceuticals
Category
growth
Teva Pharmaceuticals Q1 Update ($TEVA): Innovation and Generics drive 9th consecutive quarter of growth
TEVA: Added to position. 9 straight quarters revenue growth, $3.89B (+2% YoY). Strong innovative drugs - Austedo ($2B 2025E, +39% Q1), Ajovy (+26%), Uzedy (+156%). Generics +3% YoY. $700M cost savings by 2027, raising margins to 30%. FCF +238% YoY. PT $27 in 9-12 months.
Read full article (4 min)